Companies /Healthcare

Pulse Biosciences Inc

NASDAQ: PLSE Medical Instruments & Supplies
$44.41
▼ $1.42 (−3.10%) today
Markets closed · 5:40pm ET

PLSE at a Glance

Valuation
Market cap
$3.4B
Profitability
Revenue (TTM)
$1.5M
EPS (TTM)
$-1.21
Price
52-week range
$13 – $59
Street target
$67.67
Earnings
Next report
Feb 17, 2027

Headquartered in Miami, FL Fiscal year ends December NASDAQ: PLSE pulsebiosciences.com

About Pulse Biosciences

Pulse Biosciences is a bioelectric medicine company developing and commercializing its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology, branded nPulse. The technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue.

The company's main focus is atrial fibrillation (AF), pursued through two devices:
- The nPulse Cardiac Catheter System for endocardial AF ablation. Its U.S. IDE pivotal study, NANOPULSE-AF, completed enrollment of 169 evaluable patients, and a CE Mark is targeted for Q4 2027.
- A surgical clamp for concomitant surgical AF ablation, being evaluated in the NANOCLAMP-AF U.S. IDE pivotal study.

The company currently generates modest product revenue from the Vybrance Percutaneous Electrode System for soft tissue ablation, which is in a controlled commercial launch with a limited customer base. Vybrance is also being studied for benign thyroid nodules in the PRECISE-BTN study.

Pulse funds operations largely through equity raised under at-the-market (ATM) programs. As of September 30, 2026, it held $189.2 million in cash, cash equivalents and marketable securities. Updated

PLSE Coverage

Frequently Asked Questions

What does Pulse Biosciences do?

Pulse Biosciences is a bioelectric medicine company developing and commercializing its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology, branded nPulse. The technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue.

What is the PLSE stock price target?

The Wall Street consensus 12-month price target for PLSE is $67.67.